Stock listing
NASDAQ:BNTC Benitec Biopharma Inc. Stock
Home listing (NASDAQ) of Benitec Biopharma Inc.
Follow Benitec Biopharma Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BNTC
$7.92 USD -0.35 (-4.3%)
Close on Nov 20, 2026
- Day range
- $7.75 – $8.16 USDNov 20, 2026
- Volume
- 268,684 sharesNov 20, 2026
- Market cap
- $276.1M USDAt the close on Nov 20, 2026 · price × 34.89M shares outstanding
- 52-week range
- $7.75 – $14.39 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.77M USDMedian day 149,010 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BNTC · Home | $7.915 USD | -0.355 (-4.3%) | 268,684 | $8.00 | $8.163 | $7.75 | $8.27 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BNTC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.915 | -0.355 | -4.3% | $8.00 | $8.163 | $7.75 | 268,684 | |
| $8.27 | +0.12 | +1.5% | $8.14 | $8.51 | $8.12 | 128,831 | |
| $8.15 | -0.39 | -4.6% | $8.58 | $8.63 | $8.00 | 175,453 | |
| $8.54 | -0.50 | -5.5% | $9.06 | $9.298 | $8.51 | 133,358 | |
| $9.04 | -0.05 | -0.6% | $9.17 | $9.30 | $8.69 | 144,689 | |
| $9.09 | -0.38 | -4.0% | $9.39 | $9.39 | $8.80 | 231,626 | |
| $9.47 | +0.19 | +2.0% | $9.42 | $9.59 | $9.20 | 120,637 | |
| $9.28 | -0.59 | -6.0% | $9.86 | $10.01 | $9.24 | 105,713 | |
| $9.87 | +0.33 | +3.5% | $9.68 | $10.22 | $9.29 | 432,910 | |
| $9.54 | +0.90 | +10.4% | $8.65 | $9.56 | $8.555 | 120,361 | |
| $8.64 | -0.64 | -6.9% | $9.32 | $9.37 | $8.62 | 311,109 | |
| $9.28 | +0.88 | +10.5% | $8.67 | $9.39 | $8.67 | 298,141 | |
| $8.40 | -0.09 | -1.1% | $8.58 | $8.89 | $8.305 | 105,817 | |
| $8.49 | -0.25 | -2.9% | $8.81 | $8.94 | $8.24 | 240,632 | |
| $8.74 | -0.09 | -1.0% | $8.80 | $8.93 | $8.429 | 135,485 | |
| $8.83 | +0.03 | +0.3% | $8.85 | $9.11 | $8.73 | 162,538 | |
| $8.80 | +0.12 | +1.4% | $8.58 | $8.91 | $8.19 | 238,599 | |
| $8.68 | +0.09 | +1.0% | $8.60 | $8.849 | $8.52 | 156,893 | |
| $8.59 | -0.06 | -0.7% | $8.71 | $8.80 | $8.54 | 98,628 | |
| $8.65 | -0.17 | -1.9% | $8.91 | $8.91 | $8.53 | 158,391 | |
| $8.82 | +0.32 | +3.8% | $8.47 | $8.85 | $8.21 | 149,010 | |
| $8.50 | -0.54 | -6.0% | $9.05 | $9.22 | $8.40 | 171,850 | |
| $9.04 | +0.68 | +8.1% | $8.35 | $9.29 | $8.32 | 347,596 | |
| $8.36 | +0.25 | +3.1% | $8.13 | $8.618 | $8.00 | 194,120 | |
| $8.11 | -0.35 | -4.1% | $8.47 | $8.47 | $8.06 | 158,600 | |
| $8.46 | +0.17 | +2.1% | $8.37 | $8.758 | $8.34 | 153,700 | |
| $8.29 | -0.34 | -3.9% | $8.52 | $9.07 | $8.25 | 162,500 | |
| $8.63 | -0.44 | -4.9% | $9.08 | $9.08 | $8.51 | 151,400 | |
| $9.07 | +0.20 | +2.3% | $8.90 | $9.25 | $8.75 | 200,900 | |
| $8.87 | +0.12 | +1.4% | $8.72 | $9.03 | $8.71 | 73,000 | |
| $8.75 | -0.24 | -2.7% | $8.86 | $8.97 | $8.61 | 234,900 | |
| $8.99 | -0.01 | -0.1% | $8.81 | $9.27 | $8.80 | 190,100 | |
| $9.00 | -0.23 | -2.5% | $9.32 | $9.565 | $8.62 | 217,200 | |
| $9.23 | +0.25 | +2.8% | $9.00 | $9.99 | $8.52 | 584,200 | |
| $8.98 | -0.60 | -6.3% | $9.71 | $9.876 | $8.92 | 135,100 | |
| $9.58 | -0.42 | -4.2% | $9.94 | $10.17 | $9.465 | 103,100 | |
| $10.00 | +0.25 | +2.6% | $9.83 | $10.13 | $9.64 | 146,000 | |
| $9.75 | -0.27 | -2.7% | $10.17 | $10.17 | $9.65 | 111,000 | |
| $10.02 | +0.43 | +4.5% | $9.57 | $10.04 | $9.31 | 152,800 | |
| $9.59 | -0.05 | -0.5% | $9.70 | $9.80 | $9.306 | 107,000 | |
| $9.64 | -0.19 | -1.9% | $9.74 | $10.41 | $9.255 | 196,700 | |
| $9.83 | -1.12 | -10.2% | $10.92 | $11.32 | $9.49 | 644,200 | |
| $10.95 | +0.07 | +0.6% | $10.97 | $11.37 | $10.61 | 88,900 | |
| $10.88 | -0.14 | -1.3% | $11.12 | $11.14 | $10.74 | 121,900 | |
| $11.02 | -0.34 | -3.0% | $11.37 | $11.62 | $10.86 | 423,000 | |
| $11.36 | +0.32 | +2.9% | $11.27 | $11.55 | $11.15 | 91,300 | |
| $11.04 | -0.01 | -0.1% | $11.09 | $11.45 | $10.89 | 138,800 | |
| $11.05 | -1.03 | -8.5% | $12.11 | $12.37 | $10.96 | 263,400 | |
| $12.08 | -0.11 | -0.9% | $12.24 | $12.42 | $12.01 | 106,400 | |
| $12.19 | -0.03 | -0.2% | $12.38 | $12.51 | $12.12 | 88,600 | |
| $12.22 | -0.23 | -1.8% | $12.31 | $12.47 | $12.00 | 94,600 | |
| $12.45 | -0.275 | -2.2% | $12.68 | $13.00 | $12.22 | 70,000 | |
| $12.73 | +0.045 | +0.4% | $12.55 | $13.00 | $12.51 | 102,200 | |
| $12.68 | +0.24 | +1.9% | $12.33 | $12.83 | $12.33 | 45,000 | |
| $12.44 | -0.44 | -3.4% | $12.93 | $13.28 | $12.24 | 62,600 | |
| $12.88 | +0.57 | +4.6% | $12.36 | $13.19 | $12.25 | 191,400 | |
| $12.31 | +0.14 | +1.2% | $12.12 | $12.43 | $11.80 | 78,300 | |
| $12.17 | -0.30 | -2.4% | $12.37 | $12.57 | $12.01 | 60,800 | |
| $12.47 | -0.20 | -1.6% | $12.60 | $12.76 | $11.71 | 103,200 | |
| $12.67 | -0.21 | -1.6% | $13.20 | $13.21 | $12.60 | 103,200 | |
| $12.88 | -0.14 | -1.1% | $13.02 | $13.02 | $12.65 | 64,600 | |
| $13.02 | +0.31 | +2.4% | $12.79 | $13.35 | $12.76 | 255,000 | |
| $12.71 | -0.77 | -5.7% | $13.53 | $13.64 | $12.47 | 122,500 | |
| $13.48 | +0.47 | +3.6% | $13.14 | $13.98 | $13.03 | 160,100 | |
| $13.01 | -0.37 | -2.8% | $13.27 | $13.27 | $12.37 | 426,800 |
Splits
4 splits since 2015 · NASDAQ:BNTC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-17 | Consolidation | |
| 2-for-3 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-4 | Consolidation |
- Ticker
- NASDAQ:BNTC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
Latest deck · May 15, 2026
American Society of Cell & Gene Therapy 2026
Conference · 20 slides
Latest news
UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
Nov 13, 2026
Closed $9.04 (-0.6%) on Nov 13, 2026
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
Oct 28, 2026
Closed $8.80 (+1.4%) on Oct 28, 2026
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Oct 5, 2026
Closed $9.23 (+2.8%) on Oct 5, 2026
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Sep 14, 2026
Closed $11.05 (-8.5%) on Sep 15, 2026
Unleash Your Ultimate Kaiju! Godziburst and Godzilla Scramble Figures Available for Pre-Order Starting June 25
Jun 25, 2026
Closed $13.00 (-4.6%) on Jun 25, 2026
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
May 14, 2026
Closed $11.85 (+1.7%) on May 14, 2026
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Apr 28, 2026
Closed $12.17 (-3.5%) on Apr 28, 2026
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development fo...
Mar 10, 2026
Closed $12.27 (-2.2%) on Mar 10, 2026
Benitec Biopharma Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 85 in all · newest Nov 13, 2026 · oldest 2019
- Decks
- 45 decks · latest May 15, 2026
Where Benitec Biopharma Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BNTC · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BNTC | BOATS | United States | USD |
Valuation
Price/book 1.6× against a median of 3.6×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $99.78M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.46
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| TRex Bio, Inc. · NASDAQ:TRXB | US$283.1M | US$205.0M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Greenwich LifeSciences, Inc. · NASDAQ:GLSI | US$282.6M | US$276.7M | n/a | n/a | n/a | n/a | n/a | n/a | 2.80 |
| Precision BioSciences, Inc. · NASDAQ:DTIL | US$282.5M | US$228.3M | n/a | 5.1× | n/a | 5.5× | −85.6% | 0.5× | 0.30 |
| AP Biosciences, Inc. · TPEX:6945 | US$282.3M | US$215.7M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Fulcrum Therapeutics, Inc. · NASDAQ:FULC | US$281.8M | −US$17.87M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.42 |
| Circio Holding ASA · OSL:CRNA | US$281.1M | US$225.9M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | n/a |
| Relmada Therapeutics, Inc. · NASDAQ:RLMD | US$279.5M | US$77.42M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.57 |
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.1M | US$182.5M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Agenus Inc. · NASDAQ:AGEN | US$270.1M | US$218.3M | 9.2× | 1.6× | 4.0× | n/a | 22.0% | n/a | 1.80 |
| Median of the others | US$281.5M | US$217.0M | 9.2× | 5.1× | 4.0× | 3.6× | −31.8% | 0.0× | 1.39 |
Forecasts
6 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 23.32 USD · Analysts' mean
- EPS, year to Jun 2027
- -1.11 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jerel Banks | Chief Executive Officer & Chairman of the Board |
| Megan Boston | Chief Financial Officer & Director |
| Sophie Mukadam | Chief Operating Officer |
Board
| Director | Role |
|---|---|
| Jerel Banks | Chief Executive Officer & Chairman of the Board |
| David Friedman | Director |
| Edward Smith | Director |
| J. Kevin Buchi | Director |
| Kishen Mehta | Director |
| Megan Boston | Chief Financial Officer & Director |
| Peter Francis | Director |
| Sharon Mates | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 13, 2026 · Before open | −0.6% |
| Q4 2026 | Sep 14, 2026 · After close | −8.5% |
| Q3 2026 | May 14, 2026 · Before open | +1.7% |
| Q2 2026 | Feb 12, 2026 · Before open | −2.7% |
| Q1 2026 | Nov 14, 2025 | +2.9% |
| Q4 2025 | Sep 22, 2025 · After close | −2.1% |
| Q3 2025 | May 14, 2025 · Before open | +3.0% |
| Q2 2025 | Feb 14, 2025 · Before open | +16.0% |
| Q1 2025 | Nov 14, 2024 · After close | +2.7% |
| Q4 2024 | Sep 19, 2024 · Before open | +3.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | May 13, 2024 · Before open | −12.2% |
| Q2 2024 | Feb 13, 2024 · Before open | +0.0% |
| Q1 2024 | Nov 13, 2023 · Before open | +1.2% |
| Q4 2023 | Sep 21, 2023 · Before open | +0.3% |
| Q3 2023 | May 15, 2023 · Before open | +0.9% |
| Q2 2023 | Feb 13, 2023 · Before open | 0.0% |
| Q1 2023 | Nov 10, 2022 · Before open | +5.4% |
| Q4 2022 | Sep 2, 2022 · Before open | −3.5% |
| Q3 2022 | May 16, 2022 · Before open | −8.8% |
| Q2 2022 | Feb 14, 2022 · Before open | −4.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| American Society of Cell & Gene Therapy 2026 | Conference | 20 slides | May 15, 2026 |
| Investor Presentation (January 2026) | Investor deck | 43 slides | January 2026 |
| Corporate Update (November 2025) | Corporate update | 31 slides | Nov 3, 2025 |
| Investor Presentation (September 2025) | Investor deck | 34 slides | September 2025 |
| Technical Presentation (March 2025) | Technical | 31 slides | Mar 19, 2025 |
| Investor Presentation (March 2025) | Investor deck | 41 slides | March 2025 |
| Technical Presentation (October 2024) | Technical | 50 slides | Oct 14, 2024 |
| Technical Presentation (July 2024) | Technical | 6 slides | Jul 15, 2024 |
| Investor Day (April 2024) | Investor day | 71 slides | Apr 18, 2024 |
| Investor Day (April 2024) | Investor day | 71 slides | Apr 17, 2024 |
All 45 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Update: US$13.5 a share · Leerink Partners +2 Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead) Use of proceeds: Continued development of product candidate programs, working capital and general corporate purposes | Nov 6, 2025 |
| Registered direct offering of common stock Update: US$13.5 a share · Leerink Partners +2 Dealers: Leerink Partners, TD Cowen, Evercore ISI Buyers: Suvretta Capital (1,481,481 shares of common stock) Use of proceeds: Continued development of product candidate programs, working capital and general corporate purposes | Nov 6, 2025 |
| Public offering of common stock or pre-funded warrants Announced: US$13 a share · Leerink Partners +2 Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Citizens Capital Markets Use of proceeds: Continued development of product candidate programs, working capital and general corporate purposes | Mar 25, 2025 |
| Registered direct offering of common stock Announced: US$13 a share Buyers: Suvretta Capital (900,000 shares of common stock) Use of proceeds: Continued development of product candidate programs, working capital and general corporate purposes | Mar 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 75.0K | 73.0K | 59.0K | 102.0K | 12.2M | 4.40M | 195.9K | ||
| Cost of revenue | 474.0K | 160.0K | ||||||||
| Gross profit | 3.95M | 35.9K | ||||||||
| Research and development | 23.4M | 18.3M | 15.6M | 12.8M | 11.3M | 7.02M | 3.00M | 4.57M | 3.73M | 4.07M |
| Selling, general and administrative | 4.72M | 5.35M | ||||||||
| Operating income | -51.2M | -41.8M | -22.5M | -19.1M | -17.9M | -13.6M | -8.28M | 2.58M | -8.73M | -15.9M |
| Depreciation and amortization | 58.0K | 66.0K | 87.0K | 136.0K | 167.0K | 231.0K | 190.0K | 158.0K | 195.0K | 217.0K |
| EBITDA | -51.1M | -41.7M | -22.4M | -18.9M | -17.7M | -13.4M | -8.09M | 2.74M | -8.53M | -15.7M |
| Interest expense | 0 | 0 | ||||||||
| Income before tax | -45.3M | -37.2M | -21.0M | -19.0M | -17.4M | 7.91M | -299.0K | 169.0K | -8.55M | -3.35M |
| Income tax | 0 | -4.21M | -10.3M | |||||||
| Net income | -45.5M | -37.9M | -21.8M | -19.6M | -18.2M | -13.9M | -8.27M | 2.61M | -12.3M | -5.60M |
| Earnings per share, basic | -0.98 | -1.05 | -1.22 | -14.12 | -37.88 | -3.23 | -8.10 | 3.05 | -74.68 | -40.72 |
| Earnings per share, diluted | -0.98 | -1.05 | -1.22 | -14.12 | -37.88 | -3.23 | -8.10 | 3.05 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 180.0M | 97.7M | 50.9M | 2.48M | 4.06M | 19.8M | 9.80M | 15.7M | 16.2M | 17.4M |
| Short-term investments | 22.0K | 76.8K | ||||||||
| Receivables | 4.27M | 3.49M | ||||||||
| Inventory | 0 | -65.1K | ||||||||
| Current assets | 181.7M | 98.5M | 51.7M | 3.73M | 4.82M | 20.6M | 10.8M | 18.8M | 21.0M | 22.2M |
| Property, plant and equipment | 178.0K | 131.0K | 179.0K | 87.0K | 222.0K | 375.0K | 374.0K | 470.0K | 319.0K | 445.0K |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 182.6M | 99.6M | 52.2M | 4.46M | 5.97M | 21.4M | 11.6M | 19.2M | 21.4M | 22.7M |
| Accounts payable | 426.1K | 133.7K | ||||||||
| Current liabilities | 5.34M | 1.80M | 4.92M | 3.98M | 2.53M | 1.37M | 1.14M | 2.64M | 2.56M | 864.5K |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 0 | 0 | ||||||||
| Total liabilities | 5.61M | 2.30M | 4.96M | 4.26M | 3.09M | 1.37M | 1.35M | 2.64M | 2.61M | 891.4K |
| Shareholders' equity | 177.0M | 97.3M | 47.2M | 202.0K | 2.88M | 20.0M | 10.2M | 16.6M | 13.8M | 21.6M |
| Shares outstanding | 34.4M | 26.3M | 10.1M | 1.67M | 480.7K | 8.17M | 1.11M | 856.8K | 165.1K | 137.6K |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -16.5M | -23.6M | -19.4M | -18.0M | -15.9M | -12.8M | -7.54M | 4.79M | -9.79M | -8.30M |
| Capital spending | -105.0K | -18.0K | -179.0K | -1.00K | -13.0K | -221.0K | -95.0K | -404.0K | -61.0K | -131.4K |
| Free cash flow | -16.6M | -23.6M | -19.6M | -18.0M | -15.9M | -13.1M | -7.63M | 4.39M | -8.61M | -8.44M |
| Cash from investing | -105.0K | -18.0K | -179.0K | -1.00K | -13.0K | -221.0K | -94.0K | -400.0K | -147.0K | -302.0K |
| Cash from financing | 99.0M | 70.5M | 68.0M | 16.0M | 22.5M | 1.77M | 8.51M | 7.94M | ||
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 8.82M | 8.07M | ||||||||
| Change in cash | 82.2M | 46.9M | 48.4M | -1.59M | -15.7M | 9.97M | -1.29M | -855.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 8-K · Current report | Oct 28, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 5, 2026 | Current report | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| 8-K · Current report | Sep 24, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 22, 2026 | Other filings | SEC |
| S-3 · Registration statement | Sep 14, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-K · Annual report | Sep 14, 2026 | Annual report | SEC |
| 8-K · Current report | Sep 14, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 28, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 20, 2026 | Other filings | SEC |
| 10-K/A · Annual report, amended | Mar 20, 2026 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Feb 24, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Feb 12, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Feb 11, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Feb 10, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 30, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 2, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 12, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 5, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 3, 2025 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Oct 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 14, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Sep 30, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 25, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 22, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 22, 2025 | Results | SEC |
| 10-K · Annual report | Sep 22, 2025 | Annual report | SEC |
| 8-K · Current report | Sep 12, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 9, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 3, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jun 2, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 29, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 29, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 23, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 28, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 28, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 27, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Mar 26, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 26, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Feb 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 27, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 3, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Dec 31, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 8-K · Current report | Dec 6, 2024 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 18, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Nov 14, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 12, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 8, 2024 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 1, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 25, 2024 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Oct 23, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 22, 2024 | Meeting notice | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| 424B5 · Prospectus | Oct 15, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Oct 11, 2024 | Meeting notice | SEC |
| 8-K · Current report | Oct 11, 2024 | Material contract | SEC |
| 8-K · Current report | Oct 8, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Oct 1, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 30, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2024 | Results | SEC |
| 10-K · Annual report | Sep 26, 2024 | Annual report | SEC |
| 8-K · Current report | Sep 4, 2024 | Management or board change | SEC |
| DEF 14A · Proxy statement | Jul 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 19, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 15, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Jul 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | May 29, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 29, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 23, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 22, 2024 | Other filings | SEC |
| S-1 · Registration statement | May 15, 2024 | Offer document | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 3 · Initial statement of ownership | May 2, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Apr 29, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 29, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 29, 2024 | Big-stake notice | SEC |
| D | Apr 25, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 18, 2024 | Material contract | SEC |
| 8-K · Current report | Apr 18, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 11, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 1, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 28, 2024 | Other filings | SEC |
| DEL AM | Feb 26, 2024 | Other filings | SEC |
| S-3 · Registration statement | Feb 23, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Feb 13, 2024 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Dec 22, 2023 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 11, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 7, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 30, 2023 | Current report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Oct 20, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 20, 2023 | Meeting notice | SEC |
| 8-K · Current report | Oct 16, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 28, 2023 | Current report | SEC |
| 8-K · Current report | Sep 21, 2023 | Results | SEC |
| 10-K · Annual report | Sep 21, 2023 | Annual report | SEC |
| 8-K · Current report | Sep 18, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 11, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 25, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 21, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 18, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 18, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2023 | Material contract | SEC |
| 8-K · Current report | Aug 10, 2023 | Current report | SEC |
| 424B4 · Prospectus | Aug 10, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 9, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 7, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 3, 2023 | Other filings | SEC |
This page holds 200 of 336 filings. Open Filings
Cap table
Built by 6ix from Benitec Biopharma Inc.’s releases · as of Sep 30, 2026
- Common shares
- 34,889,313
- Fully diluted
- 34,889,313
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 34,889,313 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 30, 2026 | 34,889,313 |
| Sep 30, 2026 | 34,889,313 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sharon Mates Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); PureTech Health PLC (Director · Since at least Apr 27, 2026); Intra-Cellular Therapies Inc (Chairman and CEO, Director · Aug 29, 2013 – Apr 2, 2025 · Past) | Director · Since at least Nov 3, 2025 |
| Aaron Cowen Other companies: Veradermics, Incorporated (Director · Since at least Feb 4, 2026) | Director · Since at least Sep 26, 2024 |
| David Friedman Other companies: Veradermics, Incorporated (Board Member · Since at least Nov 5, 2026) | Director · Since at least Mar 25, 2025 |
| Edward Smith | Director · Since at least Nov 5, 2026 |
| Jerel Banks | Chief Executive Officer & Chairman of the Board · Since at least Apr 15, 2020 |
| J. Kevin Buchi | Director · Since at least Jun 30, 2026 |
| Kishen Mehta | Director · Since at least Mar 25, 2025 |
| Megan Boston | Chief Financial Officer, Director · Since at least Sep 23, 2025 |
| Peter Francis | Director · Since at least Apr 15, 2020 |
| Sophie Mukadam | Chief Operating Officer · Since at least Jan 1, 2025 |
Log in to ask 6ix AI your own questions about Benitec Biopharma Inc.